% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kaaks:136740,
author = {R. Kaaks$^*$ and R. Turzanski-Fortner$^*$ and A.
Hüsing$^*$ and M. Barrdahl$^*$ and M. Hopper and T. S.
Johnson$^*$ and A. Tjønneland and L. Hansen and K. Overvad
and A. Fournier and M.-C. Boutron-Ruault and M. Kvaskoff and
L. Dossus and M. Johansson and H. Boeing and A. Trichopoulou
and V. Benetou and C. La Vecchia and S. Sieri and A.
Mattiello and D. Palli and R. Tumino and G. Matullo and N.
C. Onland-Moret and I. T. Gram and E. Weiderpass and M.-J.
Sánchez and C. Navarro Sanchez and E. J. Duell and E.
Ardanaz and N. Larranaga and E. Lundin and A. Idahl and K.
Jirström and B. Nodin and R. C. Travis and E. Riboli and M.
Merritt and D. Aune and K. Terry and D. W. Cramer and K. S.
Anderson},
title = {{T}umor-associated autoantibodies as early detection
markers for ovarian cancer? {A} prospective evaluation.},
journal = {International journal of cancer},
volume = {143},
number = {3},
issn = {0020-7136},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2018-01178},
pages = {515 - 526},
year = {2018},
abstract = {Immuno-proteomic screening has identified several
tumor-associated autoantibodies (AAb) that may have
diagnostic capacity for invasive epithelial ovarian cancer,
with AAbs to P53 proteins and cancer-testis antigens (CTAGs)
as prominent examples. However, the early detection
potential of these AAbs has been insufficiently explored in
prospective studies. We performed ELISA measurements of AAbs
to CTAG1A, CTAG2, P53 and NUDT11 proteins, for 194 patients
with ovarian cancer and 705 matched controls from the
European EPIC cohort, using serum samples collected up to 36
months prior to diagnosis under usual care. CA125 was
measured using electrochemo-luminiscence. Diagnostic
discrimination statistics were calculated by strata of
lead-time between blood collection and diagnosis. With lead
times ≤6 months, ovarian cancer detection sensitivity at
0.98 specificity (SE98) varied from 0.19 $[95\%$ CI
0.08-0.40] for CTAG1A, CTAG2 and NUDT1 to 0.23 [0.10-0.44]
for P53 (0.33 [0.11-0.68] for high-grade serous tumors).
However, at longer lead-times, the ability of these AAb
markers to distinguish future ovarian cancer cases from
controls declined rapidly; at lead times >1 year, SE98
estimates were close to zero (all invasive cases, range:
0.01-0.11). Compared to CA125 alone, combined logistic
regression scores of AAbs and CA125 did not improve
detection sensitivity at equal level of specificity. The
added value of these selected AAbs as markers for ovarian
cancer beyond CA125 for early detection is therefore
limited.},
cin = {C020},
ddc = {610},
cid = {I:(DE-He78)C020-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29473162},
pmc = {pmc:PMC6019150},
doi = {10.1002/ijc.31335},
url = {https://inrepo02.dkfz.de/record/136740},
}